Abstract
A novel monoclonal antibody (BAT) to the B-lymphoblastoid cell line activates murine lymphocytes and exhibits a striking antitumor activity in mice. In order to evaluate the potential use of this antibody against human cancer, we have investigated its immuno-stimulatory properties on human peripheral blood lymphocytes (PBL). Our findings demonstrate that BAT mAb induces proliferation and cytotoxicity in human PBL against natural-killer-cell-sensitive and natural-killer-cell-resistant tumor cell lines. Interleukin-2 at a low concentration synergizes with BAT mAb in eliciting these effects. BAT mAb binds to human peripheral T cells as revealed by a double-labelling technique using anti-CD3 and BAT mAb. The molecular mass of the antigen recognized by BAT mAb was 48–50 kDa under reducing and non-reducing conditions. This study provides a basis for future experiments to evaluate the use of BAT mAb in the immunotherapy of cancer.
Key Words: Monoclonal antibody, Agonistic, Human B-lymphoblastoid, Cytotoxicity, T cell activation
Footnotes
Supported by research grant (to B.H.) from the Chief Scientist, Ministry of Health, Israel
References
- 1.Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C. B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 1993;366:76. doi: 10.1038/366076a0. [DOI] [PubMed] [Google Scholar]
- 2.Clark EA, Ledbetter JA. Amplification of the immune response by agonistic antibodies. Immunol Today. 1986;7:267. doi: 10.1016/0167-5699(86)90008-3. [DOI] [PubMed] [Google Scholar]
- 3.Dang NH, Hafler DA, Schlossman SF, Breitmeyer JB. FcR-mediated cross linking of Ta1 (CDW26) induced human T lymphocyte activation. Cell Immunol. 1990;125:42. doi: 10.1016/0008-8749(90)90061-u. [DOI] [PubMed] [Google Scholar]
- 4.De Jong R, Brouer M, Rebel VI, Van Seventer GA, Miedema F, Van Lier RAW. Generation of alloreactive cytolytic T lymphocytes by immobilized anti-CD3 monoclonal antibodies. Analysis of requirements for human cytolytic T lymphocyte differentiation. Immunology. 1990;70:357. [PMC free article] [PubMed] [Google Scholar]
- 5.Ferran C, Sheehan K, Dy M, Schrieber R, Merite S, Landais P, Noel L-H, Gran G, Bluestone J, Bach J-F, Chatenoud L. Cytokine-related syndrome following injection of anti CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol. 1990;20:509. doi: 10.1002/eji.1830200308. [DOI] [PubMed] [Google Scholar]
- 6.Freedman AS, Freeman G, Horowitz JC, Daley J, Nadler LM. B7, a B cell-restricted antigen that identified preactivated B cells. J Immunol. 1987;139:3260. [PubMed] [Google Scholar]
- 7.Hardy B, Dotan D, Novogrodsky A. A monoclonal antibody to human B-lymphoblastoid cells activates human and murine T lymphocytes. Cell Immunol. 1989;118:22. doi: 10.1016/0008-8749(89)90354-7. [DOI] [PubMed] [Google Scholar]
- 8.Hardy B, Yampolski I, Kovjazin R, Galli M, Novogrodsky A. A monoclonal antibody against a human B-lymphoblastoid cell line induces tumor regression in mice. Cancer Res. 1994;54:5793. [PubMed] [Google Scholar]
- 9.Hathcock KS, Laszlo G, Dickler HB, Bradshaw J, Linsley P, Hodes RJ. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science. 1993;262:905. doi: 10.1126/science.7694361. [DOI] [PubMed] [Google Scholar]
- 10.Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol. 1991;147:2461. [PubMed] [Google Scholar]
- 11.Jung G, Martin DE, Muller-Edberhard JH. Induction of cytotoxicity in human peripheral blood mononuclear cells by mononclonal antibody OKT3. J Immunol. 1987;139:639. [PubMed] [Google Scholar]
- 12.Koulova L, Clark EA, Shu G, Dupont B. The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+T cells. J Exp Med. 1991;173:759. doi: 10.1084/jem.173.3.759. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Labalette-Houache M, Torpier G, Capron A, Dessaint JP. Improved permeabilization procedure for flow cytometric detection of internal antigens. Analyses of interleukin-2 production. J Immunol Methods. 1991;138:143. doi: 10.1016/0022-1759(91)90162-9. [DOI] [PubMed] [Google Scholar]
- 14.Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174:561. doi: 10.1084/jem.174.3.561. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Meuer SC, Hussey RE, Fabbi M, Fox D, Acuto O, Fitzgerald KA, Nodgdon JC, Protentis JP, Schlossman SF, Reinherz EL. An alternative pathway of T cell activation. A functional role for the 50 kd T11 sheep erythrocyte receptor protein. Cell. 1984;36:897. doi: 10.1016/0092-8674(84)90039-4. [DOI] [PubMed] [Google Scholar]
- 16.Norton SC, Zuckeman L, Urdahl KB, Shefner R, Miller J, Jenkins MK. The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells. J Immunol. 1992;149:1556. [PubMed] [Google Scholar]
- 17.Siliciano RF, Pratt JC, Schmidt RE, Ritz J, Reihherz EL. Activation of cytolytic T lymphocyte and natural killer function through the T11 sheep erythrocyte binding protein. Nature. 1985;317:428. doi: 10.1038/317428a0. [DOI] [PubMed] [Google Scholar]
- 18.Testi R, Philips JH, Lanier LL. T cell activation via Leu-23 (CD69) J Immunol. 1989;143:1123. [PubMed] [Google Scholar]
- 19.Van Wauwe JP, De Mey R, Goossens JG. OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J Immunol. 1980;124:2708. [PubMed] [Google Scholar]
- 20.Yun Y-S, Hargrove ME, Ting C-C. In vivo antitumor activity of anti CD3-induced activated killer cells. Cancer Res. 1989;49:4770. [PubMed] [Google Scholar]